Boundless Bio Common Stock Performance
| BOLD Stock | USD 1.21 0.01 0.83% |
The firm shows a Beta (market volatility) of 0.65, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Boundless Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Boundless Bio is expected to be smaller as well. At this point, Boundless Bio Common has a negative expected return of -0.0019%. Please make sure to confirm Boundless Bio's expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Boundless Bio Common performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Boundless Bio Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound essential indicators, Boundless Bio is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
1 | THINK BOLD AND DREAM BIG THE LIVE MS SCHOLARSHIP RETURNS WITH 14.5 MILLION UP FOR GRABS | 10/14/2025 |
2 | JW MARRIOTT DEBUTS IN TOKYO, MARKING BOLD EXPANSION IN JAPAN WITH THE UNVEILING OF JW MARRIOTT HOTEL TOKYO | 10/23/2025 |
3 | Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights | 11/05/2025 |
4 | Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference | 11/24/2025 |
5 | Acquisition by Patterson Matthew R of 4000 shares of Boundless Bio, at 2.19 subject to Rule 16b-3 | 12/16/2025 |
6 | How rising interest rates impact Boundless Bio Inc. stock - July 2025 Rallies Risk Controlled Stock Alerts - ulpravda.ru | 12/19/2025 |
| Begin Period Cash Flow | 24.3 M | |
| Total Cashflows From Investing Activities | -26.1 M |
Boundless | Build AI portfolio with Boundless Stock |
Boundless Bio Relative Risk vs. Return Landscape
If you would invest 124.00 in Boundless Bio Common on October 4, 2025 and sell it today you would lose (4.00) from holding Boundless Bio Common or give up 3.23% of portfolio value over 90 days. Boundless Bio Common is currently does not generate positive expected returns and assumes 3.2139% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Boundless, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Boundless Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Boundless Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Boundless Bio Common, and traders can use it to determine the average amount a Boundless Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -6.0E-4
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BOLD |
Based on monthly moving average Boundless Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Boundless Bio by adding Boundless Bio to a well-diversified portfolio.
Boundless Bio Fundamentals Growth
Boundless Stock prices reflect investors' perceptions of the future prospects and financial health of Boundless Bio, and Boundless Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Boundless Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (40.95 M) | ||||
| Shares Outstanding | 22.39 M | ||||
| Price To Earning | (7.22) X | ||||
| Price To Book | 0.24 X | ||||
| EBITDA | (64.28 M) | ||||
| Net Income | (65.36 M) | ||||
| Cash And Equivalents | 351.46 M | ||||
| Cash Per Share | 7.68 X | ||||
| Total Debt | 47.63 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 12.80 X | ||||
| Book Value Per Share | 4.92 X | ||||
| Cash Flow From Operations | (60.84 M) | ||||
| Earnings Per Share | (2.66) X | ||||
| Market Capitalization | 26.86 M | ||||
| Total Asset | 206.41 M | ||||
| Retained Earnings | (201.47 M) | ||||
| Working Capital | 146.25 M | ||||
| Current Asset | 99.64 M | ||||
| Current Liabilities | 104 K | ||||
About Boundless Bio Performance
By analyzing Boundless Bio's fundamental ratios, stakeholders can gain valuable insights into Boundless Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Boundless Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Boundless Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.33) | (0.35) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (0.39) | (0.37) |
Things to note about Boundless Bio Common performance evaluation
Checking the ongoing alerts about Boundless Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Boundless Bio Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Boundless Bio Common generated a negative expected return over the last 90 days | |
| Boundless Bio Common may become a speculative penny stock | |
| Boundless Bio Common has high historical volatility and very poor performance | |
| Boundless Bio Common has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (65.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Boundless Bio Common currently holds about 351.46 M in cash with (60.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Boundless Bio Common has a very weak financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: How rising interest rates impact Boundless Bio Inc. stock - July 2025 Rallies Risk Controlled Stock Alerts - ulpravda.ru |
- Analyzing Boundless Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Boundless Bio's stock is overvalued or undervalued compared to its peers.
- Examining Boundless Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Boundless Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Boundless Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Boundless Bio's stock. These opinions can provide insight into Boundless Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Boundless Stock analysis
When running Boundless Bio's price analysis, check to measure Boundless Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boundless Bio is operating at the current time. Most of Boundless Bio's value examination focuses on studying past and present price action to predict the probability of Boundless Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boundless Bio's price. Additionally, you may evaluate how the addition of Boundless Bio to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |